GB0602855D0 - The Treatment Of Sialorrhoea - Google Patents

The Treatment Of Sialorrhoea

Info

Publication number
GB0602855D0
GB0602855D0 GB0602855A GB0602855A GB0602855D0 GB 0602855 D0 GB0602855 D0 GB 0602855D0 GB 0602855 A GB0602855 A GB 0602855A GB 0602855 A GB0602855 A GB 0602855A GB 0602855 D0 GB0602855 D0 GB 0602855D0
Authority
GB
United Kingdom
Prior art keywords
sialorrhoea
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0602855A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daniolabs Ltd
Original Assignee
Daniolabs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daniolabs Ltd filed Critical Daniolabs Ltd
Priority to GB0602855A priority Critical patent/GB0602855D0/en
Publication of GB0602855D0 publication Critical patent/GB0602855D0/en
Priority to ES12181773.8T priority patent/ES2624577T3/en
Priority to PT121817738T priority patent/PT2526943T/en
Priority to ES07705370.0T priority patent/ES2442694T3/en
Priority to EP12181773.8A priority patent/EP2526943B1/en
Priority to DK12181773.8T priority patent/DK2526943T3/en
Priority to KR1020087022049A priority patent/KR101370096B1/en
Priority to CA2642850A priority patent/CA2642850C/en
Priority to PT77053700T priority patent/PT1986642E/en
Priority to DK07705370.0T priority patent/DK1986642T3/en
Priority to MYPI20083081A priority patent/MY145817A/en
Priority to EP07705370.0A priority patent/EP1986642B1/en
Priority to JP2008554857A priority patent/JP5296557B2/en
Priority to CN200780009158.3A priority patent/CN101400347B/en
Priority to US12/279,217 priority patent/US8481583B2/en
Priority to AU2007216320A priority patent/AU2007216320B2/en
Priority to PCT/GB2007/050057 priority patent/WO2007093824A1/en
Priority to NZ570492A priority patent/NZ570492A/en
Priority to HK09108445.5A priority patent/HK1129595A1/en
Priority to US13/593,173 priority patent/US8658683B2/en
Priority to JP2013064062A priority patent/JP5744947B2/en
Ceased legal-status Critical Current

Links

GB0602855A 2006-02-13 2006-02-13 The Treatment Of Sialorrhoea Ceased GB0602855D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GB0602855A GB0602855D0 (en) 2006-02-13 2006-02-13 The Treatment Of Sialorrhoea
NZ570492A NZ570492A (en) 2006-02-13 2007-02-12 Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of excess salivation or drooling
MYPI20083081A MY145817A (en) 2006-02-13 2007-02-12 Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
JP2008554857A JP5296557B2 (en) 2006-02-13 2007-02-12 Combination of alpha-2 receptor agonist (clonidine) and antimuscarinic agent (oxybutynin) for the treatment of fluency
ES07705370.0T ES2442694T3 (en) 2006-02-13 2007-02-12 Combination of an alpha 2 receptor agonist (clonidine) and an antimuscarinic agent (oxybutynin) for the treatment of sialorrhea
EP12181773.8A EP2526943B1 (en) 2006-02-13 2007-02-12 Liquid formulation comprising an alpha-2 receptor agonist (e.g. clonidin) and oxybutynin (anti-muscarinic agent) for the treatment of sialorrhoea
DK12181773.8T DK2526943T3 (en) 2006-02-13 2007-02-12 LIQUID FORMULATING INCLUDING AN ALPHA-2 RECEPTOR AGONIST (E.g. CLONIDIN) AND OXYBUTYNIN (ANTIMUS CARININE) FOR THE TREATMENT OF SPIT
KR1020087022049A KR101370096B1 (en) 2006-02-13 2007-02-12 Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
CA2642850A CA2642850C (en) 2006-02-13 2007-02-12 Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
PT77053700T PT1986642E (en) 2006-02-13 2007-02-12 Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
DK07705370.0T DK1986642T3 (en) 2006-02-13 2007-02-12 Combination of alpha-2 receptor agonist (clonidine) and an antimuscarinic agent (oxybutynin) for the treatment of sialorrhoea
ES12181773.8T ES2624577T3 (en) 2006-02-13 2007-02-12 Liquid formulation comprising an agonist of the alpha-2 receptors (eg, clonidine) and oxybutynin (antimuscarinic agent) for the treatment of sialorrhea
EP07705370.0A EP1986642B1 (en) 2006-02-13 2007-02-12 Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
PT121817738T PT2526943T (en) 2006-02-13 2007-02-12 Liquid formulation comprising an alpha-2 receptor agonist (e.g. clonidin) and oxybutynin (anti-muscarinic agent) for the treatment of sialorrhoea
CN200780009158.3A CN101400347B (en) 2006-02-13 2007-02-12 Alpha-2 receptor agonist (clonidine) is combined with antimuscarinic drug (oxibutynin) and is used for the treatment of sialorrhea
US12/279,217 US8481583B2 (en) 2006-02-13 2007-02-12 Combination of alpha-2 receptor agonist (clonidin) and anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
AU2007216320A AU2007216320B2 (en) 2006-02-13 2007-02-12 Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
PCT/GB2007/050057 WO2007093824A1 (en) 2006-02-13 2007-02-12 Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
HK09108445.5A HK1129595A1 (en) 2006-02-13 2009-09-15 Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea 2 ()()
US13/593,173 US8658683B2 (en) 2006-02-13 2012-08-23 Combination of alpha-2 receptor agonist (clonidin) and anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
JP2013064062A JP5744947B2 (en) 2006-02-13 2013-03-26 Combination of alpha-2 receptor agonist (clonidine) and antimuscarinic agent (oxybutynin) for the treatment of fluency

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0602855A GB0602855D0 (en) 2006-02-13 2006-02-13 The Treatment Of Sialorrhoea

Publications (1)

Publication Number Publication Date
GB0602855D0 true GB0602855D0 (en) 2006-03-22

Family

ID=36119970

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0602855A Ceased GB0602855D0 (en) 2006-02-13 2006-02-13 The Treatment Of Sialorrhoea

Country Status (1)

Country Link
GB (1) GB0602855D0 (en)

Similar Documents

Publication Publication Date Title
GB0624874D0 (en) Treatment
EP1982660A4 (en) Treatment endoscope
GB0602178D0 (en) Therapeutic treatment
GB0600692D0 (en) Well treatment
GB0608655D0 (en) Therapeutic Treatment
EP2054061A4 (en) Combination therapy
GB0711342D0 (en) Well treatment
GB0610909D0 (en) Therapeutic treatment
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
GB0607952D0 (en) Novel treatment
EP2076239A4 (en) Combination therapy
GB0716784D0 (en) Well treatment
GB0723100D0 (en) Treatment of HFnEF
GB0604460D0 (en) Treatment
GB0602857D0 (en) The treatment of sialorrhoea
GB0610376D0 (en) Therapeutic treatment
PL381142A1 (en) The manner of obtaining of glicydol
GB0602858D0 (en) The treatment of sialorrhoea
GB0602855D0 (en) The Treatment Of Sialorrhoea
GB0625602D0 (en) Treatment of sialorrhoea
GB0605781D0 (en) Treatment
GB0610431D0 (en) Treatment
TJ20050863A (en) The way of narcotism treatment
GB0625603D0 (en) The treatment of hyperhidrosis
GB0603076D0 (en) The treatment of hyperhidrosis

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)